Big Buttons

• FDA doubles down: Tirzepatide is off shortage

  ...but that doesn't mean the issue is completely settled. read more →

• A couple of state updates

  Good news from Alabama, but a problem in Massachusetts read more →

• Defending GLP-1 compounding

  The latest letters APC's been sending to oppose efforts to restrict compounding read more →

• Thumbs-up for FDA crackdown

  APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →

• A PANS/PANDAS explainer

  For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →

• What, a year?

  In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Get a cease and desist letter from Verrica?

  APC has heard reports from several pharmacies that have received them — here's what to know. read more →

More News

NPR’s Sydney Lupkin continues to achieve balance and accuracy in her reporting on compounding, and we’re grateful for it. Her article this weekfocused on what will happen to compounded GLP-1s when Novo and Lilly finally get things under control and the shortage ends, and APC’s Scott Brunner is quoted. She also wrote an article back in June that provided solid advice to patients considering compounded GLP-1s. We briefed her for both.

The Washington Post’s Daniel Gilbert and Teddy Amenabar gave compounding a fair shake in their article on compounded GLP-1s last week, and a KFF Health News article by Arthur Allen also did a pretty good job being balanced about the issue (with the exception of the illustration). Both Gilbert and Allen have toured compounding pharmacies; APC also briefed them several times for their respective stories.

We’re out there, working with the press to fight misinformation about compounding, especially with GLP-1s. And with several reporters at least, our message is starting to get through.